



# Biotech Daily

Monday July 12, 2021

*Daily news on ASX-listed biotechnology companies*

- \* **ASX, BIOTECH UP: PATRYS UP 8%; OSPREY DOWN 7%**
- \* **RECCE DOSES 1<sup>st</sup> PATIENTS IN R327 TOPICAL BURNS TRIAL**
- \* **ARGENICA: ARG-007 STABLE WITH STROKE DRUGS**
- \* **CRONOS EXPECTS MARIJUANA REVENUE OF \$1.2m**
- \* **MEDLAB: AUSTRALIAN APPROVAL FOR PHASE III NANABIS PAIN TRIAL**
- \* **PATRYS: 'PAT-DX3 CROSSES BLOOD-BRAIN BARRIER, IN MICE'**
- \* **PHARMAUST, WEHI STUDY MONEPANTEL FOR HTLV-1, IN VITRO**
- \* **ZELIRA US 'OBSERVATIONAL' MARIJUANA PAIN STUDY APPROVED**
- \* **ANTERIS MACHINES COW HEART TISSUE FOR VALVES**
- \* **THORNEY, TIGA TAKE 18% OF OVENTUS**
- \* **TELEX APPOINTS KYAHN WILLIAMSON COMMS, INVESTOR RELATIONS**

## MARKET REPORT

The Australian stock market was up 0.83 percent on Monday July 12, 2021, with the ASX200 up 60.2 points to 7,333.5 points. Sixteen of the Biotech Daily Top 40 stocks were up, 14 fell and 10 traded unchanged.

Patrys was the best, up 0.4 cents or 7.8 percent to 5.5 cents, with 94.6 million shares traded. Pharmaxis climbed 7.2 percent; Compumedics improved 5.1 percent; Dimerix was up 4.2 percent; LBT and Opthea were up more than three percent; Mesoblast, Nanosonics, Optiscan, Polynovo and Pro Medicus rose two percent or more; CSL, Immutep, Neuren, Starpharma and Telix were up more than one percent; with Avita up 0.4 percent.

Osprey led the falls, down 0.1 cents or 6.7 percent to 1.4 cents, with 1.9 million shares traded. Prescient lost six percent; Alterity and Universal Biosensors were down five percent or more; Amplia fell 4.55 percent; Kazia, Oncosil and Uscom were down more than three percent; Medical Developments, Proteomics and Resonance shed two percent or more; Next Science and Volpara were down more than one percent; with Clinuvel, Cochlear and Resmed down by less than one percent.

### RECCE PHARMACEUTICALS

Recce says the first of 30 patients with infected burns have been dosed with topical spray-on R327 in a phase I/II trial at Perth.

Recce said that no adverse symptoms had been reported and interim data was expected by October with the full data by the end of the year.

In February, the company said it was ready to start the safety and efficacy trial of R327 for burn infections at Perth's Fiona Stanley Hospital (BD: Feb 16, 2021).

Today, Recce said that 10 patients would receive R327 daily for 14 days with 20 patients receiving R327 three times a week for 14 days.

Recce clinical investigator Dr Edward Raby said there was "a major unmet medical need among patients with severe burn wound infections, with this important study a key part in our work to find a solution".

Recce was up one cent or 1.1 percent to 92 cents.

### ARGENICA THERAPEUTICS

Argenica says its ARG-007 has "the potential to continue offering neuro-protection when co-administered with tissue plasminogen activator", in-vitro.

Argenica said the tissue plasminogen activator or alteplase was an intravenous medicine given to ischemic stroke victims which dissolves the stroke-causing clot and was administered after imaging diagnosis confirmed an ischemic stroke.

The company said the in-vitro, neuronal excito-toxicity model study showed that ARG-007 was resistant to proteolytic degradation when incubated with alteplase and maintained its neuro-protective properties post exposure to alteplase.

Argenica was up 1.5 cents or seven percent to 23 cents with 1.2 million shares traded.

### CRONOS AUSTRALIA

Cronos says it expects revenue for the year to June 30, 2021 to be "nearly \$1.2 million" compared to no revenue from its Adaya marijuana product last year.

Last year, Cronos said in its preliminary final report that revenue for the year to June 30, 2020 was \$123,850.

Today, the company said sales of Adaya approached \$600,000 in the three months to June 30, and it had launched THC30 with 10gm of whole marijuana flower containing 3,000mg of tetrahydrocannabinol (THC), and the 10gm THC19 containing 1,900mg THC.

Cronos was up half a cent or 4.35 percent to 12 cents.

### MEDLAB CLINICAL

Medlab says Adelaide's Bellberry has approved two sites for its trial of its marijuana-Nanabis for a phase III cancer bone pain trial.

Medlab said the sites were Sydney's Genesis Care with Prof Stephen Clarke as the principal investigator and Brisbane's Mater Hospital with Prof Phil Good as the investigator.

According to its entry on clinicaltrials.gov, the company said it would conduct a 360-participant, randomized, blinded trial aimed at showing the analgesic efficacy of Nanabis as a monotherapy in cancer patients by proving that the analgesic was significantly better than the placebo and that the magnitude of improvement was clinically important.

Medlab said it was reviewing two additional Australian sites for the trial.

Medlab was up half a cent or 3.1 percent to 16.5 cents.

## PATRY'S

Patrys says its full-sized immunoglobulin G (IgG) deoxymab antibody PAT-DX1 can cross the blood-brain barrier in mice with primary brain cancer.

In June, Patrys said that pre-clinical data for PAT-DX1 showed its ability to cross the blood-brain barrier and significantly inhibit growth of brain cancer (BD: Jun 16, 2021).

Today, the company said this was the "first time" it had shown that the full-sized PAT-DX3 was able to cross the blood-brain barrier.

Patrys said it intended to compare the effects of PAT-DX3 and PAT-DX1 on tumor reduction and survival in different primary and secondary brain cancer models.

The company said it would test PAT-DX3 as a targeting antibody for antibody drug conjugates for the delivery of therapeutic payloads.

Patrys managing director Dr James Campbell said the company was "very excited by this new discovery that opens up a range of development and partnering opportunities for the company around PAT-DX3".

"As PAT-DX3 shares a common mechanism of action with PAT-DX1, it is expected that it will also localize to both primary and secondary tumors in the brain and selectively kill cancer cells by blocking their DNA damage repair systems," Dr Campbell said.

Patrys was up 0.4 cents or 7.8 percent to 5.5 cents with 94.6 million shares traded.

## PHARMAUST, THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH

Pharmaust says it will work with the Walter and Eliza Hall Institute to investigate the effects of monepantel on human T-lymphotropic virus-1 (HTLV-1) infections, in vitro.

Pharmaust said that HTLV-1 was a cancer-inducing virus that targeted the immune system, and could cause adult T-cell leukaemia and/or lymphoma, transmitted primarily through infected bodily fluids including blood and breast milk.

The company said that about 10 million to 20 million people worldwide were infected with HTLV-1 with high recorded incidence in Japan, while several central Australian indigenous populations have infection rates of over 60 percent.

Pharmaust said that HTLV-1 infection was associated with pulmonary disease, inflammatory disorders and, in some cases, leukaemia and/or lymphoma.

The company said that the pre-clinical studies followed its Covid-19 program "aiming to broaden the scope of targets for [monepantel's] potential anti-viral activity".

Pharmaust previously said it was investigating the Elanco sheep round-worm treatment for human and canine cancer as well as severe acute respiratory syndrome coronavirus-2 (Sars-Cov-2) and motor-neuron disease.

The company said the research at WEHI would be led by Prof Marc Pellegrini, who also led the Sars-Cov-2 research, the fee payable to the Institute was "not material", and preliminary data was expected in December 2021.

Pharmaust fell 0.1 cents or 1.05 percent to 94 cents.

## ZELIRA THERAPEUTICS

Zelira says it has US approval for a 12-week observational study of its marijuana products for pain.

Zelira said the study would evaluate the safety and tolerability of its product compared to an unnamed "multi-billion-dollar big pharmaceutical company drug".

The company said it expected the study results by July 2022.

Zelira was up 0.2 cents or 4.2 percent to five cents with 4.3 million shares traded.

### ANTERIS TECHNOLOGIES

Anteris says it has developed machinery to develop consistently thin bovine pericardium, or cow heart, tissue for its Adapt-treated valve replacement products.

Anteris said the process reduced the cow pericardium thickness “to yield tissue with the desired thickness to make its [three-dimensional] single-piece aortic valves”.

The company said the tensile strength properties were equivalent to its current Adapt treated pericardium and the next step would be valve durability studies to prove equivalence between the processed tissue and native tissue.

Anteris said it has lodged patent applications to protect the development.

Anteris was up 25 cents or 3.2 percent to \$8.10.

### OVENTUS MEDICAL

Thorney Technologies and Tiga Trading say they have increased their shareholding in Oventus from 30,403,652 shares (16.72%) to 44,373,656 shares (18.36%).

The Melbourne-based Thorney and Tiga said that with the Waislitz Family Foundation and Jasforce Pty Ltd, between July 5 and 9, 2021 they bought 2,960,080 shares on market for \$305,261 or at an average price of 10.31 cents a share, in a placement on June 29 acquired 4,100,000 shares for \$492,000 or 12 cents a share and on June 15, 2021 in a five-for-22 rights offer bought 6,909,924 shares for \$829,191 or at 12 cents a share.

Last month, Oventus said its fully underwritten one-for-4.4 rights offer at 12 cents a share raised \$4.96 million taking the total raised to \$10.02 million (BD: Jun 15, 2021).

Oventus was unchanged at 11 cents.

### TELIX PHARMACEUTICALS

Telix said it has appointed Kyahn Williamson as head of corporate communications and investor relations.

Telix said that Ms Williamson was formerly the head of investor and corporate communication with WE Communications, formerly Buchan Consulting.

The company said that Ms Williamson worked with ASX-listed companies in the biotechnology sector for 15 years, designing and implementing investor relations and public relations strategies and advising on initial public offers and merger and acquisitions.

Telix was up six cents or 1.1 percent to \$5.61 with 392,250 shares traded.